Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Interferon-alpha
  • Kidney Neoplasms
  • Pyrroles

abstract

  • In patients with mRCC, sunitinib reduced tumor growth rate, g, more than did IFN-α. Correlating g with OS confirms earlier analyses suggesting g may be an important clinical trial endpoint, to be explored prospectively and in individual patients.

publication date

  • April 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3328595

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-2275

PubMed ID

  • 22344231

Additional Document Info

start page

  • 2374

end page

  • 81

volume

  • 18

number

  • 8